China-Heng Group 09 years to Rise 6 times times the story of aging persuaded private placement

In June this year, Shenzhen, a former top-ranking private equity company responsible for the research of a director to the field survey, after many contacts, the private equity group (600252.SH) Chairman of the Xu Shuqing of the story, and after the investigation back actively positions. Coincidentally。 Another private-equity firm that specializes in mining growth shares has been swapping stocks for shares that have been in the early stages of earnings, and the goal of changing positions has also been rising more than 6 times times since 2009. The private-equity firm said confidently: "The future growth of net worth depends on it."　　"The second half of the year, Thrombus production increased 2006, Guangdong private entrepreneurs Xu Shuqing 500 million yuan to take over the Heng Group, at that time, the group because of the capital chain fracture and debt, Xu Shuqing, decisively will power station and other non-performing assets, sale of real estate projects to withdraw funds, the goal of enterprise development aimed at the modernization of traditional Chinese medicine industry. "Chinese medicine is used for thousands of years in China, is actually very good things, but because the modernization of traditional Chinese medicine has just begun, many people think that the direction of the industry is still somewhat unclear." But with the improvement of the purity of traditional Chinese medicine, Chinese Medicine can also be sold to the whole world, not necessarily worse than synthetic medicine. And now the government is also promoting the trend of Chinese medicine industrialization.　　"The private equity director said that Xu Shuqing, after choosing the direction of the Chinese medicine industry, will be the main product of cardio-cerebral vascular drug thrombosis, further targeting the aging market." "China is about to enter an aging society, the elderly's microcirculation system is caused by the deterioration of human organ failure is a very important reason, and the goal of Thrombus Pass is to improve microcirculation, so the potential of the market in the future is very large."　　"The private equity director said that in the future of China, the spending on chronic illness medicine would be the biggest, even greater than the cost of an acute life-saving drug." The Thrombus pass as the main breed really for the group opened a new world.　　Since 2007, the company has been in short supply of Thrombus Tong.　　Zhong Heng Group announced the 2010-year report showed that the benefit of the leading product injection with the increase in the rate of thrombosis, the company's pharmaceutical sector to achieve total operating income of 367 million yuan, the same period last year 51.81%, to achieve ownership of the parent company's owner of the net profit of 163 million yuan, up from the same period GF Securities and pharmaceutical industry analyst Ge Jing pointed out that the first half of the pharmaceutical part of the group's contribution to the 0.59 yuan, the profits of which mainly by the thrombus through contributions. In the first half of the group, 50 million Thrombus-tong sales for the company contributed nearly 0.6 yuan per share results, in the second half of the year, the capacity limit after release, the blood clots will be significantly better in the first half, if you can achieve 120 million (50 million 2.4 times times) around the sales volume, you can achieve 0.6x2.4=　　1.44 Yuan Annual medical results. "Thrombus Tong in this year should be able to do the national Chinese medicine preparation industry in the first place, and in the next year, the two years, will be the otherOpponents far away.　　Said the director of the private equity company.　　Next year's results will double in addition to the pharmaceutical business, the company's main industry also includes real estate and new development of herbal tea drinks.　　This year, the group began to promote Turtle ling cream and drink turtle Ling Bao, and in June this year to 90 million yuan price overall acquisition of Guangxi Wuzhou Double Money Industrial Co., Ltd. 100% of the equity, a full march into the herbal tea beverage market.　　At present, the herbal tea beverage market leading products Wang old Kat growth quickly, of which the red can Wang old Kat in 2008 sales have broken through 12 billion yuan, Canton medicine Green Box Wang old Kat sales also more than 1 billion yuan.　　The directors of the private equity company said that at the previous shareholders ' meeting, the goal of the management of the group was to reach a capacity of 1 billion yuan this year, while the target for three years would be 5 billion yuan. "Now the company has begun to plan some advertising and marketing activities, according to the company's goal, light this business can support the current valuation of the group."　　"But the future development and prospects of the business still need time to observe," said the director of the private equity firm.　　As soon as he returned to Shenzhen, the private-equity researcher undertook a full-area assessment of the group. After investigation, it was found that the market is generally underestimated by the group, and the current share price is seriously undervalued.　　"The director of the private equity company said that this year, the company's performance per share of 1.4~1.5 yuan, and to the next year, the pharmaceutical business for each share of the performance contribution will reach 2.5 yuan, turtle Ling Bao can contribute 0.4 yuan per share of the performance." In this way, by the first half of next year, the market will see the company's 3-dollar earnings per share, and the price will easily break 60 yuan. The director of the private equity company said that both in product development and marketing capabilities, the group has enough qualifications to grow into a big blue chip in the pharmaceutical industry.　　In the next 3-5 years, the company's market value will be greatly increased and ranked among the forefront of pharmaceutical stocks. After the group discussion, the company entered the equity pool of the private equity fund. The June reform and Development Commission on a new round of basic drug price adjustment of a document to the first half of the scenery of the unlimited group of medical units frustrated.　　Just completed the issuance of the group in the first trading day after the deal plunged more than 8%. "We started our positions in the slump.　　"The private equity director said that, compared to more than 30 yuan in the cost of the placement, the company is expected to bring in at least six months to double the profit." Research and Marketing questioned Shenzhen another private equity manager who successfully tapped into the investment opportunities of the pharmaceutical sector in the first half of the year questioned the growth of the group: "The main business of Zhong Heng Group is too complex, not a pure medicine unit, and the follow-up research and development ability is questionable in the pharmaceutical industry. "In this respect, the directors of the private equity company who went to China-Heng Group for field research were not impressed.　　According to the director, in the investigation process, the management of the group said the company has begun to study the first imitation of the large varieties of Western medicine. "And what they're doing is some annual salesThe sale of tens of billions of agents, small varieties they do not do, this is their other extraordinary place. Said the director of the private equity company.　　At the same time, the research department of China-Heng Group and the Guangxi Zhuang Autonomous Region is a peer, Guangxi local government has said to let the company become Guangxi's pharmaceutical integration platform. But since the company's management did not disclose specific cloning targets, and when these generics can contribute to sales revenue and profits are uncertain.　　There are still people in the industry that are questioning. In addition, the "Academic marketing" model adopted by China-Heng Group for the marketing of Thrombus has also been questioned by some industry researchers.　　Some industry researchers pointed out that the sales of thrombus in the group is the use of academic meetings to invite doctors to the scene, and to "receive red envelopes" and other ways to give doctors the benefit of the opening of the product sales, but this way in the country launched a crackdown on drug trade bribery policy will face a great test. "It's said layman's terms.　　"The director of the above-mentioned private equity company said that the group is currently selling the sale to distributors, what marketing mode is decided by the Distributor, in the early stage of product launch by the company in this way both excluded the risk of enterprises in this regard, but also through concessions to distributors, strengthen the sales of products.　　In the previous shareholder meeting, Xu Shuqing has said that the company's thrombus will not continue to go agent mode, at present, gradually standardize the drug circulation link, once the drug circulation link norms, the central group will be recycled channels.　　The director of the private equity company said that once the channel is recycled, it means that the gross margin earned by the group will increase from 3 yuan to about 10 yuan per time, which has great potential. "I predict that after 3-5 years, the company brings a profit of more than 2 billion yuan a year." But the market has not yet recognized the company's potential.　　Said the director of the private equity company. Risk tip: For the potential risk factors of China-Heng Group, the directors of the private equity company said they are more concerned about the company's real estate business.　　Other private equity managers said the reason for not including China-Heng Group in the stock pool of its pharmaceutical stocks is because the group is still engaged in real estate business, and the real estate business is still one of its main directions. In addition, the latest statistics of wind information show that as of June 30 this year, a total of 25 funds settled in the Heng Group, the Fund shareholding in the share of the shares reached 30.82%.　　And all the main institutions shareholding ratio of more than 43.82%. Shenzhen, another private equity group, said that the growth of the company is good, but the institutional positions are too large, the subsequent rise in share prices may lack of new funds to promote.